Company Position Statement Regarding Recent Investigation of Senior Executives

OBI Pharma strongly denies allegations of insider trading. Since March 2016, the Shi-Lin District Prosecutor’s Office has been investigating whether senior OBI executives sold shares with foreknowledge of the results of the clinical trial of OBI-822-001. These allegations are unfounded and the facts demonstrate that these executives are innocent. OBI will continue to defend these […]